Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
This study is testing a program called HARMONY, which is a psychoeducational intervention for people newly diagnosed with hepatocellular carcinoma (HCC), a type of liver cancer. The goal is to see if HARMONY is a good fit for patients and if it's practical to study it more widely. You might be able to join if you are at least 18 years old, have been diagnosed with HCC in the last six months, and can complete study tasks in English. The study is looking to enroll about 50 participants. The main way they will measure success in this part of the study is by looking at how many people enroll within 10 weeks. The current recruitment status is unclear.
- Study design
- This study has two parts. Part 2 is a pilot randomized controlled trial (RCT) where participants will be randomly assigned to receive either HARMONY or enhanced usual care (a supportive care resource guide).
- What's involved
- Participants will complete a survey at the beginning of the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
At a glance
Conditions
NCT06541990
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Massachusetts General Hospital
Boston, Massachusettsstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Feasibility: study enrollment rate10 weeks
≥40% enrollment among consecutive eligible patients